- Home
- RMNI vs VRXA Comparison
RMNI vs VRXA Comparison
Compare RMNI & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMNI | VRXA |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.2M | 390.3M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMNI | VRXA |
|---|---|---|
| Price | $4.81 | $1.76 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 302.8K | ★ 951.5K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 197.50 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $431,496,000.00 | N/A |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | $491.00 | ★ N/A |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $2.87 | $1.70 |
| 52 Week High | $5.06 | $4.50 |
Technical Indicators
Market Signals| Indicator | RMNI | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 29.98 |
| Support Level | $3.32 | $1.74 |
| Resistance Level | $4.84 | $2.29 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 44.85 | 13.46 |
Price Performance
Historical ComparisonAbout RMNI Rimini Street Inc. (DE)
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.